Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02393859
Other study ID # 20120215
Secondary ID 2014-002476-92
Status Completed
Phase Phase 3
First received
Last updated
Start date November 10, 2015
Est. completion date November 21, 2022

Study information

Verified date May 2024
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse. In general, pediatric treatment regimens are more intense than those employed in adults and include courses of combination chemotherapy. Standard of care chemotherapy is associated with considerable toxicity. There is a lack of novel treatment options for subjects who relapse or are refractory to treatment. Therefore, innovative therapeutic approaches are urgently needed. Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19 expressing cells. This study will evaluate the event-free survival (EFS) after treatment with blinatumomab when compared to standard of care (SOC) chemotherapy. The effect of blinatumomab on overall survival and reduction of minimal residual disease compared to SOC chemotherapy will also be investigated.


Description:

Patients will be randomized in a 1:1 ratio to receive either one cycle of blinatumomab or one block of standard high-risk consolidation chemotherapy. Blinatumomab is administered as a continuous intravenous infusion (CIVI). One cycle of blinatumomab treatment includes 4 weeks of CIVI of blinatumomab. After completing consolidation therapy, the patients should undergo alloHSCT depending on their bone marrow status. The patients will be followed up until the last subject on study is 36 months following alloHSCT or has died, whichever is first.


Recruitment information / eligibility

Status Completed
Enrollment 111
Est. completion date November 21, 2022
Est. primary completion date July 17, 2019
Accepts healthy volunteers No
Gender All
Age group 0 Years to 17 Years
Eligibility Inclusion Criteria: - Subjects with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor acute lymphoblastic leukemia (ALL; as defined by International Berlin-Frankfurt-Muenster study group/International study for treatment of childhood relapsed ALL [I-BFM SG/IntReALL] criteria) - Subjects with bone marrow blast percentage < 5% (M1) or bone marrow blast percentage < 25% and =5% (M2) marrow at the time of randomization, - Age > 28 days and < 18 years at the time of informed consent/assent - Subject's legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated - Availability of the following material from relapse diagnosis for central analysis of minimal residual disease (MRD) by polymerase chain reaction (PCR): clone-specific primers and reference deoxyribonucleic acid (DNA), as well as primer sequences and analyzed sequences of clonal rearrangements (cases with isolated extramedullary relapse or cases with technical and/or logistic hurdles to obtain and process bone marrow material are exempt from providing this material. In these cases, central MRD analysis only by Flow is permitted). Exclusion Criteria: - Clinically relevant central nervous system (CNS) pathology requiring treatment (eg, unstable epilepsy). Evidence of current CNS (CNS 2, CNS 3) involvement by ALL. Subjects with CNS relapse at the time of relapse are eligible if CNS is successfully treated prior to enrollment - Peripheral neutrophils < 500/µL prior to start of treatment - Peripheral platelets < 50,000/µL prior to start of treatment - Currently receiving treatment in another investigational device or drug study or less than 4 weeks since ending treatment on another investigational device or drug study(s), procedures required by IntReALL high-risk (HR) guidelines are allowed - Chemotherapy related toxicities that have not resolved to = grade 2 (except for parameters defined in Exclusion Criteria 202, 203, 204, and 217) - Symptoms and/or clinical signs and/or radiological and/or sonographic signs that indicate an acute or uncontrolled chronic infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol - Abnormal renal or hepatic function prior to start of treatment (day 1) as defined below - Abnormal serum creatinine based on age/gender - Total bilirubin > 3.0 mg/dL prior to start of treatment (unless related to Gilbert's or Meulengracht disease) - Documented infection with human immunodeficiency virus (HIV) - Known hypersensitivity to immunoglobulins or any of the products or components to be administered during dosing (excluding asparaginase) - Post-menarchal female subject who is pregnant or breastfeeding, or is planning to become pregnant or breastfeed while receiving protocol-specified therapy and for at least 12 months after the last dose of chemotherapy - Post-menarchal female subject who is not willing to practice true sexual abstinence or use a highly effective form of contraception while receiving protocol-specified therapy and for at least 12 months after the last dose of chemotherapy - Sexually mature male subject who is not willing to practice true sexual abstinence or use a condom with spermicide while receiving protocol-specified therapy and for at least 6 months after last dose of chemotherapy. In countries where spermicide is not available, a condom without spermicide is acceptable - Sexually mature male subject who is not willing to abstain from sperm donation while receiving protocol-specified therapy and for at least 6 months after last dose of chemotherapy - Subject likely to not be available to complete all protocol-required study visits or procedures, including follow-up visits, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge - History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion - Placed into an institution due to juridical or regulatory ruling.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Blinatumomab
15 µg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
Dexamethasone
10 mg/m^2/day intravenous (IV) on Days 1-6
Vincrisitne
1.5 mg/m^2/day IV on Days 1 and 6
Daunorubicin
30 mg/m^2 IV over 24 hours on Day 5
Methotrexate
1 g/m^2 IV over 36 hours on Day 1
Ifosfamide
800 mg/m^2 IV for 1 hour on Days 2-4
PEG-asparaginase
1000 U/m^2 IV for 2 hours or intramuscularly (IM) on Day 6
Erwinia-asparaginase
In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses

Locations

Country Name City State
Argentina Research Site Ciudad Autonoma de Buenos Aires Buenos Aires
Australia Research Site Parkville Victoria
Australia Research Site Randwick New South Wales
Australia Research Site South Brisbane Queensland
Australia Research Site Westmead New South Wales
Austria Research Site Graz
Austria Research Site Innsbruck
Austria Research Site Wien
Belgium Research Site Brussels
Belgium Research Site Brussels
Belgium Research Site Gent
Belgium Research Site Leuven
Belgium Research Site Liege
Brazil Research Site Curitba Paraná
Brazil Research Site Porto Alegre Rio Grande Do Sul
Brazil Research Site Sao Paulo São Paulo
Brazil Research Site Sao Paulo São Paulo
Czechia Research Site Praha 5
Denmark Research Site Kobenhavn O
France Research Site Bordeaux Cedex
France Research Site Lille
France Research Site Lyon
France Research Site Marseille cedex 5
France Research Site Montpellier cedex 05
France Research Site Nantes cedex 1
France Research Site Paris
France Research Site Paris
France Research Site Strasbourg Cedex
France Research Site Vandoeuvre les Nancy
Germany Research Site Berlin
Germany Research Site Duesseldorf
Germany Research Site Erlangen
Germany Research Site Essen
Germany Research Site Frankfurt am Main
Germany Research Site Freiburg
Germany Research Site Giessen
Germany Research Site Hamburg
Germany Research Site Hannover
Germany Research Site Jena
Germany Research Site Kiel
Germany Research Site München
Germany Research Site Münster
Germany Research Site Tübingen
Germany Research Site Ulm
Germany Research Site Würzburg
Greece Research Site Goudi
Israel Research Site Haifa
Israel Research Site Jerusalem
Israel Research Site Petah Tikva
Israel Research Site Tel Aviv
Israel Research Site Tel Hashomer
Italy Research Site Bologna
Italy Research Site Genova
Italy Research Site Monza (MB)
Italy Research Site Napoli
Italy Research Site Padova
Italy Research Site Pavia
Italy Research Site Roma
Italy Research Site Roma
Italy Research Site Torino
Mexico Research Site Guadalajara Jalisco
Mexico Research Site Mexico Distrito Federal
Mexico Research Site Monterrey Nuevo León
Netherlands Research Site Rotterdam
Netherlands Research Site Utrecht
Norway Research Site Oslo
Poland Research Site Bydgoszcz
Poland Research Site Krakow
Poland Research Site Lublin
Poland Research Site Wroclaw
Poland Research Site Zabrze
Portugal Research Site Lisboa
Portugal Research Site Porto
Romania Research Site Bucharest
Romania Research Site Cluj-Napoca
Russian Federation Research Site Moscow
Russian Federation Research Site Saint Petersburg
Spain Research Site Barcelona Cataluña
Spain Research Site Barcelona Cataluña
Spain Research Site Boadilla del Monte Madrid
Spain Research Site El Palmar Murcia
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Malaga Andalucía
Spain Research Site Santander Cantabria
Spain Research Site Santiago de Compostela Galicia
Spain Research Site Sevilla Andalucía
Spain Research Site Valencia Comunidad Valenciana
Sweden Research Site Stockholm
Switzerland Research Site Basel
Switzerland Research Site Zuerich
Turkey Research Site Adana
Turkey Research Site Antalya
Turkey Research Site Izmir
Turkey Research Site Kayseri
United Kingdom Research Site Birmingham
United Kingdom Research Site Bristol
United Kingdom Research Site Glasgow
United Kingdom Research Site London
United Kingdom Research Site Manchester
United Kingdom Research Site Newcastle upon Tyne
United Kingdom Research Site Sheffield
United Kingdom Research Site Sutton

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Countries where clinical trial is conducted

Argentina,  Australia,  Austria,  Belgium,  Brazil,  Czechia,  Denmark,  France,  Germany,  Greece,  Israel,  Italy,  Mexico,  Netherlands,  Norway,  Poland,  Portugal,  Romania,  Russian Federation,  Spain,  Sweden,  Switzerland,  Turkey,  United Kingdom, 

References & Publications (4)

Blinatumomabe em pacientes pediátricos com leucemia linfoblástica aguda B em primeira recidiva de alto risco: um estudo de custo-efetividade. van Beurden-Tan CHY, Ribeiro RA, Seber A, de Martino Lee ML, Marçola M, Schuetz R, Loggetto SR, Maiolino A. Jornal Brasileiro de Economia da Saúde 14(1): 41-50. 10.21115/JBES.v14.n1.p41-50

Caillon M, Brethon B, van Beurden-Tan C, Supiot R, Le Mezo A, Chauny JV, Majer I, Petit A. Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France. Pharmacoecon Open. 2023 Jul;7(4):639-653. doi: 10.1007/s41669-023-00411-4. Epub 2023 Apr 18. — View Citation

Locatelli F, Eckert C, Hrusak O, Buldini B, Sartor M, Zugmaier G, Zeng Y, Pilankar D, Morris J, von Stackelberg A. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 Aug;69(8):e29715. doi: 10.1002/pbc.29715. Epub 2022 Apr 28. — View Citation

Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Mergen N, Mohammad A, Kormany WN, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) EFS is calculated from the time of randomization until the date of relapse or M2 marrow (representative bone marrow aspirate or biopsy with = 5% and < 25% blasts) after having achieved a complete remission (CR), failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with investigational product (IP) or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date.
Participants were said to be in CR when they had the following:
M1 marrow
Peripheral blood without blasts
Absence of extramedullary leukemic involvement
Months are calculated as days from randomization date to event/censor date, divided by 30.5.
As of the primary analysis data cutoff date (17 July 2019), overall median follow-up time for EFS was 22.4 months.
Primary Kaplan Meier Estimate: EFS (Final Analysis) EFS is calculated from the time of randomization until the date of relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with IP or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date.
Participants were said to be in CR when they had the following:
M1 marrow
Peripheral blood without blasts
Absence of extramedullary leukemic involvement
Months are calculated as days from randomization date to event/censor date, divided by 30.5.
At final analysis, overall median follow-up time for EFS was 51.9 months.
Secondary Kaplan Meier Estimate: Overall Survival (OS) OS was calculated from time of randomization until death due to any cause. Participants still alive were censored at the date they were last known to be alive.
Months were calculated as days from randomization date to event/censor date, divided by 30.5.
At final analysis, overall median follow-up time for OS was 55.2 months.
Secondary Percentage of Participants With an MRD Response Within 29 Days of Treatment Initiation At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory.
MRD response was defined as MRD level < 10^-4, by polymerase chain reaction (PCR) or flow cytometry, at the end of treatment (Cycle 1 Day 29) with study drug. Participants who were part of the MRD Evaluable Set and were missing the end of treatment (Cycle 1 Day 29) assessment for a respective MRD assessment method were considered not to have achieved a response.
Up to End of Treatment (Cycle 1, Day 29)
Secondary Cumulative Incidence of Relapse (CIR) CIR estimate, presented as median months to relapse, calculated from date of achievement of first CR, using the cumulative incidence method (Fine JP, Gray RJ:1999). Deaths prior to relapse not considered related to an otherwise undocumented relapse were treated as a competing risk. Participants still alive without a date of relapse were censored at the time of last follow-up.
Relapse=presence of =1 of the following:
isolated bone marrow relapse (M3 marrow [representative bone marrow aspirate or biopsy with =25% blasts] in the absence of extramedullary involvement)
combined bone marrow relapse (M2 [representative bone marrow aspirate or biopsy with =5% and <25% blasts] or M3 marrow and =1 extramedullary manifestation of acute lymphoblastic leukemia)
central nervous system extramedullary relapse
testicular extramedullary relapse
extramedullary relapse at other sites
Months were calculated as days from randomization to event/censor date, divided by 30.5.
At final analysis, the overall maximum follow-up time was 82.0 months.
Secondary Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) Adverse event (AE): any untoward medical occurrence. Serious AE: an AE meeting at least 1 of the following serious criteria: fatal; life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Severity was graded according to the Common Terminology Criteria for AEs (CTCAE) version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Investigational product (IP) in the HC3 arm refers to dexamethasone, methotrexate, daunorubicin, erwinase, ifosfamide, asparaginase, and vincristine, and in the blinatumomab arm refers to blinatumomab. Treatment-related refers to the assessment of a relationship between IP and the event. From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.
Secondary Number of Participants With TEAEs of Interest TEAEs of interest included capillary leak syndrome (CLS), cytokine release syndrome (CRS), decreased immunoglobulins (DI), elevated liver enzymes (ELE), embolic and thrombotic events (ETE), infections (INF), infusion reactions without considering duration (IRWCD), medication errors (ME), neurologic events (NE), neutropenia and febrile neutropenia (NFN), pancreatitis (PNC), tumor lysis syndrome, leukoencephalopathy, immunogenicity. Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.
Secondary Number of Participants With Shifts From Baseline Grade 0 or 1 to Worst Postbaseline Grade 3 or 4 Clinical Chemistry and Hematology Values Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Increases (?) or decreases (?) in laboratory value grades (Gr) from baseline (BL) to worst postbaseline (? PB) grade are presented. NA=not available. Up to Day 29 (± 2 days).
Secondary Kaplan-Meier Estimate of 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) The analysis of 100-day mortality after alloHSCT was assessed for participants who received an alloHSCT while in remission and did not receive any additional anti-leukemic treatment. 100-day mortality after alloHSCT was calculated relative to the date of alloHSCT.
The 100-day mortality rate after alloHSCT was defined as the percentage of participants having died up to 100 days after alloHSCT, estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants still alive were censored at the date they were last known to be alive.
From the date of alloHSCT until death/censor date; median follow up time was 1742.0 days for blinatumomab and 1619.0 days for HC3.
Secondary Number of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only) Participants receiving blinatumomab had blood samples analyzed for binding antibodies. Samples testing positive for binding antibodies were also tested for neutralizing antibodies.
Participants who were binding antibody-positive or neutralizing antibody-positive post-baseline with a negative or no result at baseline are presented.
Day 1 to Day 29.
Secondary Pharmacokinetics: Concentration at Steady State (Css) (Blinatumomab Arm Only) Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15
Secondary Pharmacokinetics: Clearance (CL) (Blinatumomab Arm Only) Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15
See also
  Status Clinical Trial Phase
Unknown status NCT02360930 - Vincristine PK and PD in the AYA Population Compared to Younger Children N/A
Recruiting NCT05306301 - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Phase 2
Not yet recruiting NCT06101381 - CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02935543 - CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL Phase 2
Active, not recruiting NCT05440409 - CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed NCT05064787 - Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy N/A
Terminated NCT02435550 - iCare for Cancer Patients N/A
Completed NCT02799147 - GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Phase 1/Phase 2
Terminated NCT02580981 - Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses N/A
Recruiting NCT04307576 - A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Phase 3
Completed NCT04942730 - Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Phase 2
Terminated NCT01761682 - Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Completed NCT04327037 - Safety of Expanded Haploidentical Natural Killer Cells for Leukemia Phase 1
Terminated NCT02349178 - Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT Phase 2
Recruiting NCT04209244 - Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia N/A
Recruiting NCT03911128 - A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
No longer available NCT00590915 - Erwinase Master Treatment Protocol N/A